Moderate alcohol consumption generally does not interfere with avanafil’s effectiveness, but excessive intake can increase the risk of dizziness, low blood pressure, and reduced erection quality. It is advisable to limit alcohol to a moderate amount when planning sexual activity.
Avanafil has one of the fastest onset times among PDE5 inhibitors, with some men reporting an erection within 15 minutes of dosing. Sildenafil typically requires 30-60 minutes, while tadalafil may need up to 2 hours for peak effect.
A prolonged erection (priapism) is a medical emergency. Seek urgent care-treatment usually involves medication to reduce blood flow to the penis and prevent permanent tissue damage.
Men with stable cardiovascular disease may use avanafil after a thorough assessment by their cardiologist or primary-care physician. The drug should be avoided in patients taking nitrates or those with uncontrolled hypertension.
Avanafil is taken on an as-needed basis. It does not accumulate significantly with daily use, and dosing is typically timed to sexual activity rather than a fixed schedule.
A high-fat meal can modestly delay the onset of avanafil but does not markedly reduce its overall efficacy. If rapid onset is important, taking the pill on an empty stomach may be preferable.
Higher doses may increase the likelihood of side effects such as headache, flushing, and dizziness. Most men start with 50 mg and titrate upward only if the lower dose is ineffective and side effects are tolerable.
No. Avanafil requires a prescription from a qualified prescriber in the United Kingdom, as it has not yet received MHRA marketing authorization for over-the-counter sale.
Combining avanafil with other PDE5 inhibitors, recreational “poppers,” or nitrate medications is contraindicated due to the risk of severe hypotension. Always disclose all medications and supplements to your doctor before starting avanafil.
Keep the tablets in their original container, protect them from extreme temperatures, and avoid leaving them in a car or direct sunlight. If you are traveling to a country where avanafil is not approved, bring a copy of your prescription and be prepared for customs checks.
Avanafil is a phosphodiesterase-type 5 (PDE5) inhibitor that belongs to the therapeutic class of erectile-dysfunction (ED) treatments. It is supplied as an oral pill in three strengths-50 mg, 100 mg and 200 mg. The medication is intended for adult men who experience difficulty achieving or maintaining an erection sufficient for satisfactory sexual activity.
In the United Kingdom, avanafil has not yet received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA). It may be available through special import arrangements or clinical-trial programmes, and any use should be under the direct supervision of a qualified prescriber. Internationally, several pharmaceutical companies market avanafil under various brand names, but the active ingredient is the same across all formulations.
Avanafil exerts its effect by selectively inhibiting the PDE5 enzyme that degrades cyclic guanosine monophosphate (cGMP) in the smooth muscle of the corpus cavernosum. When sexual stimulation occurs, nitric oxide (NO) is released from nerve endings and endothelial cells, activating guanylate cyclase and increasing cGMP levels. Elevated cGMP leads to smooth-muscle relaxation, increased blood flow into the penile tissue, and erection.
Because avanafil is highly selective for PDE5, it produces minimal inhibition of related enzymes (PDE1-4), which helps reduce the likelihood of off-target side effects. The drug is rapidly absorbed, with onset of action typically observed within 15 minutes and peak plasma concentrations reached in 30-45 minutes. Its half-life ranges from 3 to 5 hours, allowing a therapeutic window that suits spontaneous sexual activity without the need for precise timing.
Avanafil is approved in several jurisdictions for the treatment of erectile dysfunction-defined as the persistent inability to achieve or sustain an erection adequate for sexual performance. Clinical trials have demonstrated that avanafil improves erection quality compared with placebo, with response rates comparable to other PDE5 inhibitors (e.g., sildenafil, tadalafil).
The medication is indicated for adult men who have a diagnosed need for an ED therapy. It is not intended for use in women, children, or men whose erectile difficulties are caused solely by psychological factors that have not been evaluated by a healthcare professional. In practice, avanafil may be preferred by patients who desire a rapid onset of action, as its pharmacokinetic profile allows sexual activity to be initiated shortly after dosing.
Absolute contraindications
Relative contraindications
Special populations
When in doubt, a prescriber should evaluate the individual’s medical history, current medication list, and cardiovascular status before initiating therapy.
These effects are generally mild and tend to diminish with continued use.
Black-box warnings are present in regions where avanafil is approved, highlighting the risk of priapism and cardiovascular events.
Patients should provide a complete medication list, including over-the-counter drugs and herbal supplements, to their prescriber.
Note: Dosing must be individualized. The information above reflects the approved strengths (50 mg, 100 mg, 200 mg) and is not a substitute for professional medical advice.
Routine clinical monitoring for avanafil is modest but important:
Regular follow-up visits enable the prescriber to assess efficacy, adjust dosage, and reinforce safe use practices.
This article provides educational information about avanafil and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
